Clinical Center Nis

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Multiple sclerosis3 trials
• Haemophilia2 trials
• Atrial fibrillation1 trial
• Crohn's disease1 trial
• Heart failure1 trial
• Lung cancer1 trial
• Melanoma1 trial
• Stroke1 trial
• Ulcerative colitis1 trial

Phase

• Phase 39 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 2/31 trial

Status

• Active, not recruiting8 trials
• Completed3 trials
• Not yet recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Hoffmann-La Roche4 trials
• Janssen Research & Development, LLC3 trials
• Pfizer2 trials
• 4TEEN4 Pharmaceuticals GmbH1 trial
• Clinical Center Niš1 trial
• and 2 more

Running trials

• Recruiting

  Clinical Characteristics, Frailty, and Prognostic Predictors in Patients Aged 75 and Older With Acute Coronary Syndrome

  NCT07366684· Clinical Center Niš· Source

  Contact: Svetlana Apostolović, MD, PhD

• Recruiting

  A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

  NCT06832722· Phase 1/2· 4TEEN4 Pharmaceuticals GmbH· Source

  Contact: Bojan Maricic, Dr.

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

  NCT05269004· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

  NCT05270044· Phase 3· Pierre Fabre Medicament· Source

• Active, not recruiting

  A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

  NCT05119569· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

  NCT05145127· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03178552· Phase 2/3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease2 recruiting
• Heart failure1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

  NCT03938792· Phase 3· Pfizer· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source